🇺🇸 FDA
Patent

US 9303044

7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of thrombotic disorders

granted A61KA61K31/337A61K31/4353

Quick answer

US patent 9303044 (7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of thrombotic disorders) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/337, A61K31/4353, A61K31/436, A61K31/519